RT Journal Article
SR Electronic
T1 The Role of VSL#3® in the Treatment of Fatigue and Other Symptoms in Long Covid-19 Syndrome: a Randomized, Double-blind, Placebo-controlled Pilot Study (DELong#3)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.28.23291986
DO 10.1101/2023.06.28.23291986
A1 Marinoni, Beatrice
A1 Rimondi, Alessandro
A1 Bottaro, Federico
A1 Ciafardini, Clorinda
A1 Amoroso, Chiara
A1 Muià, Martina
A1 Caridi, Bruna
A1 Noviello, Daniele
A1 Bandera, Alessandra
A1 Gori, Andrea
A1 Mantero, Marco
A1 Blasi, Francesco
A1 Ferrucci, Roberta
A1 Facciotti, Federica
A1 Vecchi, Maurizio
A1 Caprioli, Flavio
YR 2023
UL http://medrxiv.org/content/early/2023/06/28/2023.06.28.23291986.abstract
AB Long COVID, also known as Post-acute COVID-19 Syndrome (PACS), is a chronic condition affecting individuals who have recovered from acute COVID-19. It is currently estimated that around 65 million people worldwide suffer from Long COVID. It is characterized by a range of symptoms, including fatigue, exertion intolerance, neurocognitive and sensory impairment, sleep disturbance, myalgia/arthralgia, and dysautonomia. Among them fatigue has emerged as a burdensome and pervasive issue, significantly impacting the quality of life and daily functioning of Long COVID patients. Alterations in the composition of the intestinal microbiota has been reported in COVID-19 patients. Dysbiosis persists even after several months of recovery from acute SARS-CoV-2 infection.Based on this evidence, we carried out a phase 3, randomized, double-blind, placebo-controlled trial aimed at evaluating the efficacy of VSL#3®, a consortium of probiotic bacterial strains, in reducing fatigue and improving various aspects of patients’ well-being in patients with Long COVID syndrome.HighlightsPatients suffering from Long-COVID manifest a variety of persistent symptoms impacting daily functioning;Fatigue emerged as a burdensome and pervasive issue, significantly impacting the quality of life;VSL#3® treatment significantly reduced the Chalder Fatigue Scale scores as compared to placeboChalder Fatigue Scale scores remained significantly reduced in the treatment group 4 weeks post intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05874089Funding StatementThis study was partially funded by Italian Ministry of Health, Current research IRCCS. This study received a financial non-conditioning grant by Actial Farmaceutica s.r.l. which also provided the probiotic product.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approval by the ethics committee of IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico di Milano (number S62043).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors